CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc.

1:14-cv-01289

Overview

Case Number 1:14-cv-01289
Filing Date 2014-10-10
Status Terminated
Termination Date 2019-05-01
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Par Pharmaceutical Inc. Operating Company

Represented By

8 Attorneys Listed

Roger J Chin

Email: roger.chin@lw.com

Parker M. Tresemer

UNDELIVERABLE EMAIL 2/12/2019

Marc N. Zubick

Email: marc.zubick@lw.com

Katharine Lester Mowery

Richards, Layton & Finger, PA

Tel: +1 (302) 651-7623

Richards, Layton & Finger, PA, One Rodney Square

Emily Sauter

UNDELIVERABLE EMAIL 2/12/2019

Daniel G. Brown

Email: daniel.brown@lw.com

Brenda L. Danek

Email: brenda.danek@lw.com

Steven J. Fineman

Richards, Layton & Finger, PA

Tel: +1 (302) 658-6541

Richards, Layton & Finger, PA, One Rodney Square

Novartis AG Operating Company

Represented By

2 Attorneys Listed

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

Novartis Pharmaceuticals Corporation Operating Company

Represented By

7 Attorneys Listed

Nicholas N. Kallas

Email: nkallas@venable.com

Laura K. Fishwick

Email: lfishwick@venable.com

Corinne E. Atton

Email: catton@venable.com

Christopher E. Loh

Email: cloh@venable.com

Christina Schwarz

Email: cschwarz@venable.com

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 5 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts Counterparts in force
🏛️
USPTO PTAB Trials 6 proceedings
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (5): GB 🇺🇸 US 🌐 PCT
Parallel Proceedings Across Jurisdictions (6 found):
PTAB: 6
USPTO PTAB Trial 2016-05-26
IPR2016-01103

Breckenridge Pharmaceutical, Inc. v. Novartis AG

U.S. Continuation Sibling (5665772)
Status: Institution Denied
USPTO PTAB Trial 2016-05-26
IPR2016-01102

Roxane Laboratories, Inc. et al. v. Novartis AG

U.S. Continuation Sibling (5665772)
Status: Final Written Decision
USPTO PTAB Trial 2016-05-17
IPR2016-01059

Par Pharmaceutical, Inc. et al. v. Novartis AG

U.S. Continuation Sibling (5665772)
Status: Institution Denied
USPTO PTAB Trial 2016-05-10
IPR2016-01023

BRECKENRIDGE PHARMACEUTICAL, INC. v. Novartis AG

U.S. Continuation Sibling (5665772)
Status: Final Written Decision
USPTO PTAB Trial 2015-10-26
IPR2016-00084

Par Pharmaceutical, Inc. et al. v. Novartis AG

U.S. Continuation Sibling (5665772)
Status: Final Written Decision
USPTO PTAB Trial 2015-10-26
IPR2016-00078

Par Pharmaceutical, Inc. et al. v. Novartis AG

U.S. Continuation Sibling (6455518)
Status: Institution Denied
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

4 Patents

There are 4 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US5665772
O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
Filed: 1993-09-24
Issued: 1997-09-09
Expired (Term Ended) +2176d PTA
Expires: 2019-09-09
US6004973
Pharmaceutical compositions comprising rafamycin coprecipitates
Filed: 1996-07-12
Issued: 1999-12-21
Expired (Term Ended)
Expires: 2016-07-12
US6455518
Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin
Filed: 2001-01-11
Issued: 2002-09-24
Expired (Term Ended)
Expires: 2021-01-11
US6239124
Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin
Filed: 1997-07-29
Issued: 2001-05-29
Expired (Term Ended) +13d PTA
Expires: 2017-08-11

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Statutorily Barred

Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, injunctive relief is barred.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+2176 days) / In re Cellect scrutiny applies.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

25

Dispositive

0

Granted

1

Denied

0

Pending / Review

20

Motions by Category

Claim Construction / Markman Filing 12 Procedural / Extension Motion 13

Key Dispositive Motions & Rulings

Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME the Deadline for Submitting a Joint Status Report and Joint Proposed Form of Order and Judgment to April 30, 2019 - filed by Novartis...
Entry #199 • 2019-04-25 Document →
Procedural / Extension Motion Pending
SO ORDERED, re (126 in 15-cv-78-RGA, 199 in 14-cv-1289-RGA, 126 in 14-cv-1494-RGA) STIPULATION TO EXTEND TIME the Deadline for Submitting a Joint Status Report ...
Entry #— • 2019-04-25
Procedural / Extension Motion Granted
ORDER Granting (35 in 17-cv-420-RGA, 212 in 14-cv-1196-RGA, 129 in 15-cv-128-RGA, 116 in 14-cv-1494-RGA, 115 in 15-cv-78-RGA, 188 in 14-cv-1289-RGA, 128 in 14-c...
Entry #190 • 2019-02-25 Document →
Procedural / Extension Motion Pending / Under Review
RESPONSE to 188 MOTION for Extension of Time to Submit Joint Status Report, filed by Novartis AG, Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibi...
Entry #189 • 2019-02-21 Document →
Procedural / Extension Motion Pending / Under Review
MOTION for Extension of Time to Submit Joint Status Report - filed by Par Pharmaceutical Inc., Par Pharmaceutical Inc., Breckenridge Pharmaceutical Inc., West-W...
Entry #188 • 2019-02-20 Document →
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME to Submit Proposed Final Judgment to May 2, 2017 - filed by Novartis AG, Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Ente...
Entry #173 • 2017-04-27 Document →

Docket Entries

(287 total)
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed against Par Pharmaceutical Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 311-1605184.) - filed by Novartis Pharmaceuticals Corporation, Novartis AG. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Civil Cover Sheet)(dmp, ) (Entered: 10/14/2014)

Entry #1 • 2014-10-10
1
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed against Par Pharmaceutical Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 311-1605184.) - filed by Novartis Pharmaceuticals Corporation, Novartis AG. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Civil Cover Sheet)(dmp, ) (Entered: 10/14/2014)

Entry #1 • 2014-10-10
2
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed against Par Pharmaceutical Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 311-1605184.) - filed by Novartis Pharmaceuticals Corporation, Novartis AG. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Civil Cover Sheet)(dmp, ) (Entered: 10/14/2014)

Entry #1 • 2014-10-10
2
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed against Par Pharmaceutical Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 311-1605184.) - filed by Novartis Pharmaceuticals Corporation, Novartis AG. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Civil Cover Sheet)(dmp, ) (Entered: 10/14/2014)

Entry #1 • 2014-10-10
2
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed against Par Pharmaceutical Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 311-1605184.) - filed by Novartis Pharmaceuticals Corporation, Novartis AG. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Civil Cover Sheet)(dmp, ) (Entered: 10/14/2014)

Entry #1 • 2014-10-10
2

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc